ISSN: 1885-5857 Impact factor 2023 7.2
Vol. 73. Num. 12.
Pages 994-1002 (December 2020)

Original article
Impact of COVID-19 on ST-segment elevation myocardial infarction care. The Spanish experience

Impacto de la COVID-19 en el tratamiento del infarto agudo de miocardio con elevación del segmento ST. La experiencia española

Oriol Rodríguez-LeorabcBelén Cid-ÁlvarezdArmando Pérez de PradoeXavier RossellofgbSoledad OjedahAna SerradoribRamón López-PalopjJavier Martín-MoreiraskbJosé Ramón RumorosolÁngel CequiermBorja IbáñezbfnIgnacio Cruz-GonzálezkbRafael RomagueramRaúl Morenoob for the Working Group on the Infarct Code of the Interventional Cardiology Association of the Spanish Society of Cardiology Investigators Manuel VillaaaRafael Ruíz-SalmerónbbFrancisco MolanoccCarlos SánchezddErika Muñoz-GarcíaeeLuís ÍñigoffJuan HerradorggAntonio Gómez-MencherohhAntonio Gómez-MencheroiiJuan CaballerojjSoledad OjedakkMérida CárdenasllLivia GheorghemmJesús OnetonnFrancisco MoralesooFélix ValenciappJosé Ramón RuízqqJosé Antonio DiarterrPablo AvanzasssJuan RondánttVicente PeraluuLucía Vera PernasettivvJulio HernándezwwFrancisco BosaxxPedro Luís Martín Lorenzoyy...María Pilar Portero Pérezch
Rev Esp Cardiol. 2020;73:975-710.1016/j.rec.2020.09.023
Borja Ibáñez

Options

Abstract
Introduction and objectives

The COVID-19 outbreak has had an unclear impact on the treatment and outcomes of patients with ST-segment elevation myocardial infarction (STEMI). The aim of this study was to assess changes in STEMI management during the COVID-19 outbreak.

Methods

Using a multicenter, nationwide, retrospective, observational registry of consecutive patients who were managed in 75 specific STEMI care centers in Spain, we compared patient and procedural characteristics and in-hospital outcomes in 2 different cohorts with 30-day follow-up according to whether the patients had been treated before or after COVID-19.

Results

Suspected STEMI patients treated in STEMI networks decreased by 27.6% and patients with confirmed STEMI fell from 1305 to 1009 (22.7%). There were no differences in reperfusion strategy (> 94% treated with primary percutaneous coronary intervention in both cohorts). Patients treated with primary percutaneous coronary intervention during the COVID-19 outbreak had a longer ischemic time (233 [150-375] vs 200 [140-332] minutes, P<.001) but showed no differences in the time from first medical contact to reperfusion. In-hospital mortality was higher during COVID-19 (7.5% vs 5.1%; unadjusted OR, 1.50; 95%CI, 1.07-2.11; P <.001); this association remained after adjustment for confounders (risk-adjusted OR, 1.88; 95%CI, 1.12-3.14; P=.017). In the 2020 cohort, there was a 6.3% incidence of confirmed SARS-CoV-2 infection during hospitalization.

Conclusions

The number of STEMI patients treated during the current COVID-19 outbreak fell vs the previous year and there was an increase in the median time from symptom onset to reperfusion and a significant 2-fold increase in the rate of in-hospital mortality. No changes in reperfusion strategy were detected, with primary percutaneous coronary intervention performed for the vast majority of patients. The co-existence of STEMI and SARS-CoV-2 infection was relatively infrequent.

Keywords

STEMI
COVID-19
Primary angioplasty
STEMI network

Identify yourself

Not yet a subscriber to the journal?

Purchase access to the article

By purchasing the article, the PDF of the same can be downloaded

Price: 19,34 €

Phone for incidents

Monday to Friday from 9am to 6pm (GMT+1) except for the months of July and August, which will be from 9am to 3pm

Calls from Spain 932 415 960
Calls from outside Spain +34 932 415 960
Copyright © 2020. Sociedad Española de Cardiología
Are you a healthcare professional authorized to prescribe or dispense medications?